21 February 2019: Commencement of Assay Service Using the OncoGuide™ NCC Oncopanel System in Cancer Genome Profiling

On January 31, 2019, Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) launched the OncoGuide™ NCC Oncopanel System (generic name: genetic mutation analysis set (for cancer genome profiling)), for which the Company received manufacturing and marketing approval on December 25, 2018. Accordingly, in February 2019 Sysmex’s subsidiary, RIKEN GENESIS Co., Ltd. (HQ: Shinagawa-ku, Tokyo, Japan; President & CEO: Naoto Kondo), will begin providing an assay service as a healthcare service to be assessed using the OncoGuide™ NCC Oncopanel System and next-generation sequencers.